Idefirix

Imlifidase, the active ingredient in Idefirix, is an IgG‑degrading enzyme (IdeS) presented as an intravenous solution for infusion use. It is employed to rapidly reduce donor‑specific antibodies in patients undergoing HLA‑incompatible kidney transplantation, facilitating successful graft acceptance. Its rapid IgG cleavage enables a transient immunosuppressive window, allowing clinicians to proceed with transplantation without prolonged desensitization protocols.

GNH USA supplies Idefirix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics where required to maintain product integrity.

Idefirix is used in the field of transplant immunology to manage antibody‑mediated barriers to kidney transplantation.

HLA‑incompatible kidney transplantation: enables transplantation by rapidly reducing donor‑specific antibodies. Sensitized renal transplant candidates: facilitates graft acceptance when conventional desensitization fails. Pre‑transplant antibody reduction: provides rapid IgG depletion to allow timely organ allocation.

Idefirix may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions such as flushing, chills, or fever. - Headache or mild dizziness. - Nausea or vomiting. - Transient hypotension during infusion.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Serum sickness‑like manifestations. - Opportunistic infections due to temporary immunosuppression.

Prior to initiating Idefirix therapy, clinicians should consider several precautionary measures.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against infant risk. Infection risk: monitor for opportunistic infections during the transient immunosuppressive period. Renal function: no dose adjustment required, but graft function should be closely observed. Concomitant immunosuppressants: adjust other agents as clinically indicated. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idefirix can interact with other therapies, requiring careful management.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment and up to three months after. - Complement inhibitors: may increase risk of severe infections. - High‑dose IVIG: can neutralize Imlifidase activity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor coagulation parameters due to possible infusion‑related reactions. - Corticosteroids: may mask infusion reactions; adjust monitoring accordingly. - Other monoclonal antibodies: assess for additive immunosuppression.